Freshfields advised Patient Square Capital and its Elevage Medical Technologies (‘Elevage’) platform on an investment by Elevage and Prudential Assurance Company Limited (acting by its investment manager M&G Investment Management Limited) (‘M&G’) in 4basebio PLC (AIM: 4BB), an AIM-listed company that develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions. The investment will consist of a £40.0 million issuance of new shares and the acquisition of £29.4 million of shares from certain existing shareholders. Following completion, Elevage and M&G will together hold 29.9% of 4basebio. Learn more about this transaction here. The cross-border Freshfields team was led by private capital partners Ian Bushner, Tamara Young and Charles Hayes and senior associate Olivia Mackay.